Home/Filings/4/0001235802-20-000119
4//SEC Filing

Eggenberg Michael 4

Accession 0001235802-20-000119

CIK 0001453593other

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 4:34 PM ET

Size

11.6 KB

Accession

0001235802-20-000119

Insider Transaction Report

Form 4
Period: 2020-10-01
Eggenberg Michael
Director10% Owner
Transactions
  • Award

    Common Stock

    2020-10-01$1.07/sh+11,969,619$12,807,49215,300,688 total(indirect: See Footnotes)
  • Award

    Common Stock

    2020-10-01$1.07/sh+46,784,775$50,059,70952,702,384 total(indirect: See Footnotes)
Holdings
  • Common Stock

    70,423
Footnotes (5)
  • [F1]See Exhibit 99.1
  • [F2]These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
  • [F3]Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.
  • [F4]These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.
  • [F5]These shares are to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the Reporting Person remaining a director of the Company through the vesting date.

Issuer

Xtant Medical Holdings, Inc.

CIK 0001453593

Entity typeother

Related Parties

1
  • filerCIK 0001732521

Filing Metadata

Form type
4
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 4:34 PM ET
Size
11.6 KB